Becton, Dickinson and Company (NYSE:BDX) Announces Earnings Results

Becton, Dickinson and Company (NYSE:BDX) released its quarterly earnings data on Thursday. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09, FiscalAI reports. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. The business’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.68 earnings per share. Becton, Dickinson and Company updated its FY 2026 guidance to 12.620-12.720 EPS.

Here are the key takeaways from Becton, Dickinson and Company’s conference call:

• Third-quarter results exceeded expectations, with revenue of $5.0 billion up 4.4%, adjusted operating margin of 24.9%, and adjusted EPS of $3.23, up 4.9%.
• Growth was broad-based, with more than 90% of the portfolio delivering high-single-digit growth and double-digit expansion in biologic drug delivery, advanced patient monitoring, PureWick, advanced tissue regeneration, and pharmacy automation. BD also cited share gains and strong momentum from new product launches and targeted commercial investments.
• BD raised the midpoint of its fiscal 2026 adjusted EPS outlook to $12.62–$12.72 and expects revenue growth toward the high end of its low-double-digit FX-neutral range; currency is currently expected to provide an approximately 100-basis-point revenue tailwind.
• Management expects fiscal 2027 revenue growth to remain in the low-single-digit range, partly because the end of Alaris remediation creates an approximately 200-basis-point headwind. Tariffs reduced third-quarter margin by about 110 basis points, while oil, resin costs, and broader market conditions remain risks.
• Year-to-date free cash flow rose 45% to $1.7 billion, supporting $3.1 billion of shareholder returns, including approximately $2.3 billion in share repurchases and $0.9 billion in dividends.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX traded up $6.74 during midday trading on Thursday, reaching $177.40. The company had a trading volume of 3,285,180 shares, compared to its average volume of 1,774,036. The stock has a market cap of $48.88 billion, a P/E ratio of 44.91, a P/E/G ratio of 12.16 and a beta of 0.19. The company’s 50 day moving average price is $153.78 and its 200 day moving average price is $162.41. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

More Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD reported fiscal Q3 revenue of approximately $5.0 billion, up 5.4% year over year and ahead of the $4.89 billion consensus estimate. Broad growth across its Medical Essentials and Interventional segments helped offset weaker areas. BD Reports Third Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Adjusted diluted EPS was $3.23, beating analysts’ $3.14 estimate by $0.09. The company raised its fiscal 2026 adjusted EPS guidance to $12.62-$12.72, above the roughly $12.56 consensus, and expects revenue growth toward the high end of its previous range. Becton Dickinson Signals Strong Growth Momentum By Raising Profit Outlook
• Positive Sentiment: BD reported solid cash-flow improvement: year-to-date cash from continuing operations rose 33.3% to $2.1 billion, while free cash flow increased 44.6% to $1.7 billion. This supports balance-sheet flexibility and the company’s earnings-quality narrative. BD Reports Third Quarter Fiscal 2026 Financial Results

Wall Street Analysts Forecast Growth

BDX has been the topic of several recent research reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $210.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday. TD Cowen raised their target price on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday. Weiss Ratings downgraded Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Wells Fargo & Company raised their price objective on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Finally, Piper Sandler lowered their target price on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a report on Friday, April 17th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $183.53.

Insider Activity

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 5,189 shares of company stock worth $765,661. Insiders own 0.40% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares in the last quarter. Empowered Funds LLC lifted its position in shares of Becton, Dickinson and Company by 20.4% during the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after acquiring an additional 1,354 shares in the last quarter. United Bank grew its position in shares of Becton, Dickinson and Company by 23.9% in the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock valued at $887,000 after purchasing an additional 993 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Becton, Dickinson and Company by 365.1% during the 2nd quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock valued at $5,491,000 after purchasing an additional 25,022 shares during the period. Finally, NewEdge Advisors LLC lifted its holdings in Becton, Dickinson and Company by 34.7% during the 2nd quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after purchasing an additional 6,058 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.